A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis - Related Studies

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

This study has been completed.

Study NCT00002016. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cytomegalovirus Retinitis
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Cytomegalovirus Infections
		Immunologic Deficiency Syndromes
		Infection
		Retinitis
		Syndrome

3	More general conditions related to this trial
		Disease
		DNA Virus Infections
		Eye Diseases
		Eye Infections
		Eye Infections, Viral
		Herpesviridae Infections
		Immune System Diseases
		Lentivirus Infections
		Pathologic Processes
		Retinal Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Sevirumab

5	Additional drug interventions recognized in this trial
		Antibodies, Monoclonal

6	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		Sandoz Inc.